U.S. health officials are advancing a plan to permit specialty pharmacies to produce specific peptides . This initiative followed a submission of an interim access policy to the White House for review. Peptides, largely unregulated injections, have gained popularity among individuals interested in various wellness applications, including muscle building and energy boosting. These uses are not approved by the Food and Drug Administration (FDA).
Peptides are the building blocks of proteins and have been utilized in medications for conditions like diabetes and weight loss. However, the peptides currently under consideration have not undergone the standard rigorous vetting process. Concerns regarding these products include potential contamination, allergic reactions, and tumor growth, as previously identified by the FDA . The FDA previously placed several injectable peptides, including BPC-157 , on a list of substances deemed too risky for compounding.
Recent recommendations from an external FDA advisory panel supported easing restrictions on certain peptides. The proposed policy aims to allow pharmacies to temporarily compound popular peptides, such as BPC-157 , without triggering enforcement actions. This approach, known as enforcement discretion, allows selective non-enforcement of regulations. The proposal reflects a broader effort by administration officials to address access to unproven products within the Make America Healthy Again (MAHA) movement.
Several telehealth providers, including Hims & Hers and Noom, have announced plans to offer peptides to their customers should the federal government ease access to these products. The market for peptides is estimated to potentially reach $2 billion to $3 billion.